Home › Ewing Sarcoma › New Jersey
Ewing Sarcoma clinical trials in New Jersey
4 studies for Ewing Sarcoma are looking for participants at sites in New Jersey.
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
- Memorial Sloan Kettering at Basking Ridge (Consent and Follow Up), Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent and Followup), Middletown
RecruitingObservational study
Ages 4 and older · All sexes · Updated Apr 17, 2026 · NCT03442465From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.